In what represents its first patenting, Austin, Texas-based Slipstream Solutions LLC is seeking protection for systems and methods for treating fluid stasis (e.g., edema) that employ an airstream to move static fluid to natural drainage areas such as lymph nodes or ducts.

Scientists from the Australian National University have discovered the gene mutation responsible for causing psoriasis, and the findings could lead to improved diagnosis and treatment for patients with psoriasis and psoriatic arthritis, a chronic inflammatory skin disease. “We were able to identify the gene that could be important in enabling this progression from a skin-only condition to a skin-and-joint condition,” lead study author Chelisa Cardinez told BioWorld.

Aryl hydrocarbon receptor (AhR) signaling regulates gene expression in immune and skin cells and plays a critical role in maintaining skin homeostasis.

Nearly a year after Prometheus Biosciences Inc. sold for $10.8 billion to Merck & Co. Inc., its former CEO, Mark McKenna, is back in the game with Mirador Therapeutics Inc. Many of his former Prometheus colleagues have joined McKenna. Getting the band back together, McKenna told BioWorld, “is the ultimate compliment.” Mirador just launched with more than $400 million to develop therapies for treating immune-mediated inflammatory and fibrotic diseases.

Researchers from the University of Illinois at Chicago and University of Arizona presented the discovery and preclinical evaluation of a novel BD1-selective BET inhibitor, XL-126, being developed as a potential anti-inflammatory agent.

Nine-year-old IFM Therapeutics LLC has notched yet another big deal as Novartis AG will acquire all the outstanding capital stock of IFM Due Inc., a subsidiary of privately held IFM in an agreement that began five years ago. The newest deal brings IFM $90 million up front and makes it eligible for up to $745 million in milestone payments for a deal value of $835 million.

Wegovy (semaglutide) has racked up another indication. The U.S. FDA approved the injectable for reducing risk of major adverse cardiovascular events such as death, heart attack or stroke and for long-term weight management. The approval expands the drug’s potential. The mighty glucagon-like peptide 1 receptor agonist from Novo Nordisk A/S was already approved for those age 12 and older who are obese and for some overweight adults with weight-related problems.

Monte Rosa Therapeutics Inc. has initiated IND-enabling studies with MRT-8102, a potent, highly selective and orally bioavailable NIMA-related kinase 7 (NEK7)-directed molecular glue degrader.